NLS Pharmaceutics Announces Company Update on Strategic Partnerships
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
- Members of Executive Leadership Team to Discuss Company Update on Strategic Discussions and Timeline of Phase 3,
- NLS to Webcast its Event Friday, October 20 at 11:00am ET
- 执行领导团队成员将讨论公司关于战略讨论的最新情况和第三阶段的时间表，
- NLS 将于美国东部时间 10 月 20 日星期五上午 11:00 通过网络直播其活动
ZURICH, SWITZERLAND / ACCESSWIRE / October 12, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced plans to issue an important update on discussion the company is having regarding strategic partnerships, including Timeline for the company's Phase 3 program in narcolepsy
瑞士苏黎世/ACCESSWIRE/2023 年 10 月 12 日/ 专注于发现和开发针对罕见和复杂中枢神经系统疾病患者的创新疗法的瑞士临床阶段生物制药公司NLS Pharmaceutics Ltd.（纳斯达克股票代码：NLSP）（纳斯达克股票代码：NLSP）（纳斯达克股票代码：NLSPW）（“NLSP” 或 “公司”）今天宣布，计划发布该公司有关战略合作伙伴关系讨论的重要最新情况，包括该公司第三阶段项目的时间表发作性睡病
The event will be held October 20, 2023, at 11:00 am ET and may will include a video stream on the Investors section of the Company's website. A replay will be available on the NLS' website within 48 hours after the event.
该活动将于美国东部时间2023年10月20日上午11点举行，并可能包括公司网站的 “投资者” 部分的视频直播。重播将在赛事结束后的48小时内在NLS的网站上公布。
About NLS Pharmaceutics Ltd.
关于 NLS 制药有限公司
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS Pharmaceutics Ltd.（纳斯达克股票代码：NLSP）是一家处于开发阶段的全球生物制药公司，与世界一流的合作伙伴和国际公认的科学家合作，专注于为医疗需求未得到满足的罕见复杂中枢神经系统（CNS）疾病患者发现和开发创新疗法。NLS 总部位于瑞士，成立于 2015 年，由一支经验丰富的管理团队领导，在开发和商业化候选产品方面有着良好的记录。欲了解更多信息，请访问。
For additional information:
欲了解更多信息：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
玛丽安·兰伯森（投资者和媒体）
NLS 制药有限公司
+1 239.682.8500
ml@nls-pharma.com
SOURCE: NLS Pharmaceutics AG
来源： NLS 制药股份有限公司